Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Zojer · SciRah

Researcher profile · Semantic Scholar

N. Zojer

Share profile

N. Zojer — researcher profile on SciRah

h-index: 34
Works: 229
Citations: 4,696

Most-cited papers

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
C. Kornauth, T. Pemovska, G. Vladimer, G. Bayer +66 more
2021Cancer Discovery166 citations Open access
Semantic Scholar
High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
D. Heintel, A. Rocci, H. Ludwig, A. Bolomsky +7 more
2013British Journal of Haematology129 citations Open access
Semantic Scholar
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
H. Ludwig, M. Boccadoro, P. Moreau, J. San-Miguel +28 more
2020Leukemia123 citations Open access
Semantic Scholar
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R. Hájek, T. Masszi, M. Petrucci, A. Palumbo +28 more
2016Leukemia116 citations Open access
Semantic Scholar
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
H. Ludwig, H. Kasparu, C. Leitgeb, E. Rauch +7 more
2014Blood100 citations Open access
Semantic Scholar
The myeloma stem cell concept, revisited: from phenomenology to operational terms
H. Johnsen, M. Bøgsted, A. Schmitz, J. Bødker +11 more
2016Haematologica63 citations Open access
Semantic Scholar
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
H. Ludwig, P. Sonneveld, T. Facon, J. San-Miguel +32 more
2021The Lancet Haematology57 citations Open access
Semantic Scholar
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
A. Bolomsky, K. Schlangen, W. Schreiner, N. Zojer +1 more
2016Journal of Hematology & Oncology54 citations Open access
Semantic Scholar
Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
H. Ludwig, Dejan Milosavljević, O. Berlanga, N. Zojer +3 more
2015American journal of hematology/oncology43 citations Open access
Semantic Scholar
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
J. Caers, Carlos Fernández de Larrea, X. Leleu, R. Heusschen +12 more
2016The Oncologist39 citations Open access
Semantic Scholar
SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis
H. Ludwig, S. Kainz, M. Schreder, N. Zojer +1 more
2023EClinicalMedicine35 citations Open access
Semantic Scholar
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure
N. Worel, G. Fritsch, H. Agis, Alexandra Böhm +16 more
2017Journal of clinical apheresis35 citations
Semantic Scholar
Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro.
A. Bolomsky, M. Schreder, T. Meissner, D. Hose +3 more
2014Experimental Hematology34 citations Open access
Semantic Scholar
Fixed duration vs continuous therapy in multiple myeloma.
H. Ludwig, N. Zojer
2017Hematology. American Society of Hematology. Education Program29 citations Open access
Semantic Scholar
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
A. Bolomsky, R. Heusschen, K. Schlangen, K. Stangelberger +5 more
2017Haematologica27 citations Open access
Semantic Scholar
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
H. Ludwig, E. Rauch, Thomas Kuehr, Z. Adam +8 more
2015Haematologica27 citations Open access
Semantic Scholar
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
A. Bolomsky, D. Hose, M. Schreder, A. Seckinger +5 more
2015Journal of Hematology & Oncology27 citations Open access
Semantic Scholar
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1
C. Pfeiffer, A. Grandits, H. Asnagli, A. Schneller +7 more
2023Leukemia24 citations
Semantic Scholar
Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma
A. Bolomsky, M. Schreder, W. Hübl, N. Zojer +2 more
2016Leukemia and Lymphoma23 citations
Semantic Scholar
Massive parallel IGHV gene sequencing reveals a germinal center pathway in origins of human multiple myeloma
G. Cowan, N. Weston-Bell, D. Bryant, A. Seckinger +3 more
2015OncoTarget22 citations Open access
Semantic Scholar
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials
T. Heinicke, R. Krahl, C. Kahl, M. Cross +18 more
2021Annals of Hematology21 citations Open access
Semantic Scholar
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
H. Ludwig, W. Poenisch, S. Knop, A. Egle +13 more
2019British Journal of Cancer21 citations Open access
Semantic Scholar
The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene
A. Bolomsky, J. Muller, K. Stangelberger, M. Lejeune +11 more
2020British Journal of Haematology18 citations Open access
Semantic Scholar
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
H. Ludwig, W. Pönisch, S. Knop, A. Egle +19 more
2019Leukemia and Lymphoma18 citations Open access
Semantic Scholar
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
A. Bolomsky, Juho J Miettinen, A. Malyutina, A. Besse +16 more
2021Blood Advances17 citations Open access
Semantic Scholar
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
A. Bolomsky, W. Hübl, S. Spada, E. Müldür +9 more
2017American journal of hematology/oncology12 citations Open access
Semantic Scholar
Synergistic interaction between HDAC and MCL-1 inhibitors through downregulation of BCL-XL in multiple myeloma
A. Schneller, N. Zojer, A. Bolomsky, H. Ludwig
2021Haematologica9 citations Open access
Semantic Scholar
Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study
D. Niederwieser, Verena S. Hoffmann, M. Pfirrmann, H. Al-Ali +35 more
20169 citations Open access
Semantic Scholar
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
S. Knop, Thomas Stuebig, M. Kull, R. Greil +16 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptesed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma
H. Ludwig, K. Weisel, M. Petrucci, X. Leleu +10 more
20148 citations
Semantic Scholar
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
D. Niederwieser, Thomas Lang, R. Krahl, T. Heinicke +49 more
2023Annals of Hematology7 citations Open access
Semantic Scholar
Higher Leukemia Free Survival after Post-Induction Hematopoietic Cell Transplantation Compared to Consolidation Therapy in Patients >60 Years with Acute Myelogenous Leukemia (AML): Report from the AML 2004 East German Study Group (OSHO)
D. Niederwieser, H. Al-Ali, R. Krahl, C. Kahl +24 more
20146 citations
Semantic Scholar
Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial
H. Ludwig, E. Gunsilius, M. Fridrik, R. Greil +7 more
20165 citations
Semantic Scholar
Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
H. Ludwig, B. Hausmann, M. Schreder, W. Pönisch +13 more
2020eJHaem4 citations Open access
Semantic Scholar
Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)
H. Ludwig, S. Sormann, N. Zojer, J. Andel +16 more
2019Blood4 citations
Semantic Scholar
The chemokine CXCL9 (MIG) is an independent predictor of overall survival in newly diagnosed multiple myeloma
A. Bolomsky, M. Schreder, N. Zojer, H. Ludwig
20154 citations
Semantic Scholar
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma
Heinz Ludwig, T. Melchardt, S. Sormann, M. Schreder +22 more
2024American journal of hematology/oncology3 citations Open access
Semantic Scholar
Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma
A. Bolomsky, Fred Gruber, K. Stangelberger, L. Furchtgott +9 more
2018Blood3 citations
Semantic Scholar
Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an attractive Novel Drug Target in Multiple Myeloma and its associated Bone Disease
R. Heusschen, A. Bolomsky, K. Schlangen, K. Schonfelder +5 more
20172 citations
Semantic Scholar
Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance
H. Ludwig, W. Pönisch, A. Egle, S. Knop +11 more
20172 citations
Semantic Scholar
Vemurafenib Inhibits Myeloma Cell Growth Independent Of BRAF V600E Mutations, Potentiates The Activity Of Established Anti-Myeloma Drugs, but impairs Osteogenesis Via An HGF Autocrine Loop In Bone Marrow Stromal Cells
A. Bolomsky, H. Ludwig, N. Zojer
20132 citations
Semantic Scholar
Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
H. Ludwig, T. Melchardt, S. Sormann, N. Zojer +22 more
2022Blood1 citations Open access
Semantic Scholar
P-104: Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma
J. Huber, A. Malyutina, A. Bolomsky, N. Zojer +7 more
2022Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
P-061: Single-cell whole-exome DNA sequencing traces clonal trajectory in paired evolution of MGUS to multiple myeloma
N. Ansari-Pour, S. Salatino, N. Weston-Bell, D. Bryant +7 more
2021Clinical Lymphoma, Myeloma & Leukemia1 citations
Semantic Scholar
SARS-CoV-2 vaccination in patients with solid tumors or hematological malignancies: Is the pandemic over for fully vaccinated patients?
N. Zojer
2021memo - Magazine of European Medical Oncology1 citations Open access
Semantic Scholar
Single-cell exomes in an index case of amp1q21 multiple myeloma reveal more diverse mutanomes than the whole population.
D. Bryant, W. Tapper, N. Weston-Bell, A. Bolomsky +5 more
2018Blood1 citations Open access
Semantic Scholar
Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
H. Ludwig, D. Lechner, E. Gunsilius, M. Fridrik +9 more
20171 citations
Semantic Scholar
Preclinical Evaluation of the First in Class BMI1 Inhibitor PTC-028 Confirms Potent Efficacy to Target BMI1-Addiction in Multiple Myeloma
A. Bolomsky, R. Heusschen, K. Stangelberger, M. Josephine +5 more
20171 citations
Semantic Scholar
Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma
A. Bolomsky, R. Heusschen, K. Schlangen, K. Schonfelder +5 more
20161 citations
Semantic Scholar
Focus on multiple myeloma at ASH 2015
N. Zojer
2016memo - Magazine of European Medical Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Ludwig×35
Invite
H. Ludwig — researcher profile on SciRah
A. Bolomsky×19
Invite
A. Bolomsky — researcher profile on SciRah
M. Schreder×18
Invite
M. Schreder — researcher profile on SciRah
R. Greil×12
Invite
R. Greil — researcher profile on SciRah

×9

Invite

J. Caers — researcher profile on SciRah

Invite

A. Petzer — researcher profile on SciRah

Invite

K. Weisel — researcher profile on SciRah

Invite

S. Knop — researcher profile on SciRah

E. Gunsilius×8

Invite

E. Gunsilius — researcher profile on SciRah

D. Niederwieser×7

Invite

D. Niederwieser — researcher profile on SciRah

Invite

A. Egle — researcher profile on SciRah

Invite

R. Hájek — researcher profile on SciRah